Venous thrombosis in oral contraceptive users and the presence of the JAK2 V617F mutation

Elvira Grandone; Donatella Colaizzo; Giovanni L. Tiscia; Patrizia Vergura; Elena Chinni; Luigi Iannaccone; Iole Antinolfi; Maria A. Guardascione; Maurizio Margaglione

doi:10.1160/TH07-09-0570

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2008; 99(03): 640-642
DOI: 10.1160/TH07-09-0570

Letters to the Editor

Schattauer GmbH

Venous thrombosis in oral contraceptive users and the presence of the JAK2 V617F mutation

Authors

Elvira Grandone

¹Atherosclerosis and Thrombosis Unit, I.R.C. C.S. Casa Sollievo della Sofferenza, S. Giovanni R (FG)
Donatella Colaizzo

¹Atherosclerosis and Thrombosis Unit, I.R.C. C.S. Casa Sollievo della Sofferenza, S. Giovanni R (FG)
Giovanni L. Tiscia

¹Atherosclerosis and Thrombosis Unit, I.R.C. C.S. Casa Sollievo della Sofferenza, S. Giovanni R (FG)
Patrizia Vergura

¹Atherosclerosis and Thrombosis Unit, I.R.C. C.S. Casa Sollievo della Sofferenza, S. Giovanni R (FG)
Elena Chinni

²Medical Genetics, University of Foggia, Foggia, Italy
Luigi Iannaccone

³Thrombosis and Haemostasis Centre, Cardarelli Hospital, Naples, Italy
Iole Antinolfi

³Thrombosis and Haemostasis Centre, Cardarelli Hospital, Naples, Italy
Maria A. Guardascione

⁴Gastroenterology Department, Cardarelli Hospital, Naples, Italy
Maurizio Margaglione

¹Atherosclerosis and Thrombosis Unit, I.R.C. C.S. Casa Sollievo della Sofferenza, S. Giovanni R (FG)

²Medical Genetics, University of Foggia, Foggia, Italy

Abstract

Full Text

References

References
1 Middeldorp S, Meijers JCM, van den Ende AE. et al. Effects on coagulation of levonorgestrel- and desogestrel- containing low dose oral contraceptives: a cross-over study. Thromb Haemost 2000; 84: 4-8.
2 Tans G, Curvers J, Middeldorp S. et al. A randomized cross-over study on the effects of levonorgestreland desogestrel- containing low dose oral contraceptives on the anticoagulant pathways. Thromb Haemost 2000; 84: 15-21
3 Vandenbroucke JP, Koster T, Briet E. et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-1457.
4 Jick H, Jick S, Gurewich W. et al. Risk of idiopathic venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-1593.
5 Wu O, Robertson L, Twaddle S. et al The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis. Br J Haematol 2005; 131: 80-90.
6 Vayá A, Mira Y, Mateo J. et al. Prothrombin G20210A mutation and oral contraceptive use increase upper-extremity deep vein thrombotic risk. Thromb Haemost 2003; 89: 452-457.
7 Dentali F, Crowther M, Ageno W. Thrombophilic abnormalities, oral contraceptives, and the risk of cerebral vein thrombosis: a meta-analysis. Blood 2006; 107: 2766-2773.
8 Harward TR, Green D, Bergan JJ. et al. Mesenteric venous thrombosis. J Vasc Surg 1989; 9: 328-333.
9 Hassan A. Oral contraceptive-induced mesenteric venous thrombosis with resultant intestinal ischemia. J Clin Gastroenterol 1999; 29: 90-95.
10 Abdu RA, Zakhour BJ, Dallis DJ. Mesenteric venous thrombosis —1911 to 1984. Surgery 1987; 101: 383-388.
11 Kaleya RN, Boley SJ. Mesenteric venous thrombosis. Najarian JS, Delaney JP. Progress in gastrointestinal surgery. Chicago: Year Book Medical; 1989: 417-425.
12 Kumar S, Sarr MG. Kamatah Mesenteric venous thrombosis. N Engl J Med 2001; 345: 1683-1688.
13 Brodmann S, Passweg JR, Gratwohl A. et al. Myeloproliferative disorders: complications, survival and causes of death. Ann Hematol 2000; 79: 312-318.
14 Baxter EJ, Scott LM, Campbell PJ. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
15 James C, Ugo V, Le Couedic JP. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
16 Plumé G, Vayá A, Ferrando F. et al. JAK2V617F mutation as a marker of a latent myeloproliferative disorder in a patient with Budd-Chiari syndrome and factor V Leiden mutation. Thromb Haemost 2007; 98: 681-682.
17 Kralovics R, Passamonti F, Buser AS. et al. A gainof- function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
18 Colaizzo D, Amitrano L, Tiscia GL. et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 2007; 5: 55-61.
19 Pierre R, Imbert M, Thiele J. et al. Pathology and genetics of tumors of haematopoietic and lymphoid tissues. The World Health Organization classification of tumors. Lyon: IARCPress; 2001: 32-44.
20 Reed DL, Coon WW. Thromboembolism in patients receiving progestational drugs. N Engl J Med 1963; 269: 62-63.
21 Primignani M, Barosi G, Bergamaschi G. et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006; 44: 1528-1534.
22 De Stefano V, Fiorini A, Rossi E. et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007; 5: 708-714.